Laurus Labs Limited - Asset Resilience Ratio

Latest as of September 2025: 0.74%

Laurus Labs Limited (LAURUSLABS) has an Asset Resilience Ratio of 0.74% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of Laurus Labs Limited to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

Rs697.20 Million
≈ $7.54 Million USD Cash + Short-term Investments

Total Assets

Rs94.15 Billion
≈ $1.02 Billion USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2015–2025)

This chart shows how Laurus Labs Limited's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Laurus Labs Limited.

Liquid Assets Composition Over Time

This chart breaks down Laurus Labs Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Laurus Labs Limited (LAURUSLABS) investment intensity to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Rs633.80 Million 0.67%
Short-term Investments Rs63.40 Million 0.07%
Total Liquid Assets Rs697.20 Million 0.74%

Asset Resilience Insights

  • Limited Liquidity: Laurus Labs Limited maintains only 0.74% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Laurus Labs Limited Industry Peers by Asset Resilience Ratio

Compare Laurus Labs Limited's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
Drug Manufacturers - Specialty & Generic 1.54%
Yunnan Baiyao Group Co Ltd
SHE:000538
Drug Manufacturers - Specialty & Generic 8.38%
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
Drug Manufacturers - Specialty & Generic 6.62%
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
Drug Manufacturers - Specialty & Generic 4.94%
Harbin Gloria Pharmaceuticals
SHE:002437
Drug Manufacturers - Specialty & Generic 9.04%
Jiuzhitang Co Ltd
SHE:000989
Drug Manufacturers - Specialty & Generic 7.86%
Renhe Pharmacy Co Ltd
SHE:000650
Drug Manufacturers - Specialty & Generic 37.54%
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
Drug Manufacturers - Specialty & Generic 0.29%

Annual Asset Resilience Ratio for Laurus Labs Limited (2015–2025)

The table below shows the annual Asset Resilience Ratio data for Laurus Labs Limited.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-03-31 0.57% Rs528.20 Million
≈ $5.71 Million
Rs93.36 Billion
≈ $1.01 Billion
+0.33pp
2024-03-31 0.23% Rs195.50 Million
≈ $2.11 Million
Rs83.87 Billion
≈ $907.03 Million
-0.15pp
2023-03-31 0.38% Rs294.00 Million
≈ $3.18 Million
Rs76.60 Billion
≈ $828.44 Million
+0.06pp
2022-03-31 0.32% Rs222.40 Million
≈ $2.41 Million
Rs69.68 Billion
≈ $753.57 Million
-0.36pp
2021-03-31 0.68% Rs390.70 Million
≈ $4.23 Million
Rs57.51 Billion
≈ $621.92 Million
+0.68pp
2020-03-31 0.00% Rs880.00K
≈ $9.52K
Rs37.50 Billion
≈ $405.58 Million
+0.00pp
2019-03-31 0.00% Rs740.00K
≈ $8.00K
Rs33.31 Billion
≈ $360.26 Million
+2.21pp
2018-03-31 -2.20% Rs-664.70 Million
≈ $-7.19 Million
Rs30.17 Billion
≈ $326.25 Million
+0.24pp
2017-03-31 -2.44% Rs-648.62 Million
≈ $-7.01 Million
Rs26.53 Billion
≈ $286.96 Million
-2.09pp
2016-03-31 -0.35% Rs-81.68 Million
≈ $-883.34K
Rs23.03 Billion
≈ $249.07 Million
+3.48pp
2015-03-31 -3.84% Rs-706.89 Million
≈ $-7.64 Million
Rs18.43 Billion
≈ $199.28 Million
--
pp = percentage points

About Laurus Labs Limited

NSE:LAURUSLABS India Drug Manufacturers - Specialty & Generic
Market Cap
$11.41 Billion
Rs1.05 Trillion INR
Market Cap Rank
#2024 Global
#78 in India
Share Price
Rs1954.00
Change (1 day)
+0.30%
52-Week Range
Rs832.30 - Rs1969.00
All Time High
Rs1969.00
About

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and oral solid formulations for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It… Read more